HUTCHMED (China) (HMDCF) Construction in Progress (2015 - 2016)
HUTCHMED (China)'s (HMDCF) quarterly Construction in Progress came in at $406000.0 in Q2 2016, down 28.4% quarter-over-quarter from $567000.0 in Q4 2015.
Powered by 
Analysis
HUTCHMED (China) (HMDCF) Construction in Progress (2015 - 2016) Analysis & Trends
HUTCHMED (China) (HMDCF) has reported Construction in Progress for 2 consecutive years, with $406000.0 the latest figure, recorded in Q2 2016.
- On a quarterly basis, Construction in Progress changed N/A year-over-year to $406000.0 in Q2 2016; TTM through Jun 2016 was $406000.0, a N/A change from a year earlier, with the FY2015 full-year figure at $567000.0, changed N/A from the prior year.
- Construction in Progress was $406000.0 for Q2 2016 at HUTCHMED (China), down from $567000.0 in the prior quarter.
- Over five years, Construction in Progress peaked at $567000.0 in Q4 2015 and troughed at $406000.0 in Q2 2016.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Construction in Progress (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.55 Bn | 197.56 Bn | 7.24 Bn | - |
| 2 | Gilead Sciences | 181.17 Bn | 177.99 Bn | 6.22 Bn | - |
| 3 | Vertex Pharmaceuticals | 132.18 Bn | 124.33 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 82.50 Bn | 74.50 Bn | 3.93 Bn | - |
| 5 | Argenx Se | 61.66 Bn | 56.48 Bn | 1.37 Bn | - |
| 6 | Moderna | 54.61 Bn | 49.47 Bn | 52.00 Mn | - |
| 7 | Alnylam Pharmaceuticals | 34.17 Bn | 30.86 Bn | 992.69 Mn | - |
| 8 | Biogen | 31.36 Bn | 30.07 Bn | 1.96 Bn | - |
| 9 | Roivant Sciences | 30.04 Bn | 30.04 Bn | 1.16 Mn | - |
| 10 | HUTCHMED (China) | 376.85 Mn | 391.04 Mn | - | - |